(-)-p-Bromotetramisole Oxalate (Synonyms: (-)-p-Bromotetramisole, L-para-Bromotetramisole) |
Catalog No.GC14520
One-Click Copy Product Info
|
(-)-p-Bromotetramisole Oxalate(L-p-bromotetramisole) es un inhibidor potente e inespecífico de la fosfatasa alcalina.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 62284-79-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
(-)-p-Bromotetramisole Oxalate(L-p-bromotetramisole) es un inhibidor potente e inespecífico de la fosfatasa alcalina [1-2].
(-)-p-Bromotetramisole Oxalate (1 mM) aumentó el eflujo de yoduro estimulado por cAMPy, por sí mismio, estimuló un flujo mayor que el evocado por los agonista de cAMP, lo que sugiere que puede promover la apertura del regulador de conductancia transmembrana de la fibrosis quística humana (CFTR) en células CHO[3]. En las células PC12, (-)-p-Bromotetramisole Oxalate (0.3 mM) mejora la liberación de norepinefrina (NA) estimulada por innomicina[4].
(-)-p-Bromotetramisole Oxalate(30 mg/kg; ivgtt) inhibió significativamente la elevación del MABP inducida por norepinefrina y la resistencia vascular renal. Reduce la respuesta vascular renal y de la presión arterial a la norepinefrina[5]. La infusión sistémica de (-)-p-Bromotetramisole Oxalate (0.8 ml/min de 10 mM I-p-Bromotetramisole oxalate; ivgtt) aumenta la excreción fraccional de fosfato (FEPi) en ratas de Sprague-Dawley[6].
References:[1]. Borgers M. The cytochemical application of new potent inhibitors of alkaline phosphatases. J Histochem Cytochem. 1973 Sep;21(9):812-24. doi: 10.1177/21.9.812. PMID: 4741290.[2]. Borgers M, Thoné F. The inhibition of alkaline phosphatase by L-p-bromotetramisole. Histochemistry, 1975, 44(3): 277-280.[3]. Lansdell KA, Kidd JF, et,al. Regulation of murine cystic fibrosis transmembrane conductance regulator Cl- channels expressed in Chinese hamster ovary cells. J Physiol. 1998 Nov 1;512 ( Pt 3)(Pt 3):751-64. doi: 10.1111/j.1469-7793.1998.751bd.x. PMID: 9769419; PMCID: PMC2231228.[4]. Kitamura T, Murayama T, et,al. Enhancement of Ca2+-induced noradrenaline release by vanadate in PC12 cells: possible involvement of tyrosine phosphorylation. Brain Res. 2000 Jan 31;854(1-2):165-71. doi: 10.1016/s0006-8993(99)02299-4. PMID: 10784118.[5]. Jackson EK, Zhang Y,et,al. Alkaline Phosphatase Inhibitors Attenuate Renovascular Responses to Norepinephrine. Hypertension. 2017 Mar;69(3):484-493. doi: 10.1161/HYPERTENSIONAHA.116.08623. Epub 2017 Jan 30. PMID: 28137984; PMCID: PMC5310812.[6]. Onsgard-Meyer M, McCoy AL, et,al. Effect of bromotetramisole on renal phosphate excretion. Proc Soc Exp Biol Med. 1996 Nov;213(2):193-5. doi: 10.3181/00379727-213-44050. PMID: 8931664.
| Experimentos celulares [1]: | |
Líneas celulares | Células PC12 |
Método de preparación | Las células PC12 premarcadas se incubaron con vehículo o 5 µM de ionomicina en presencia de 2 mM de CaCl2. (-)-p-Bromotetramisole Oxalate (BTO) se añadió aún más a la mezcla de ensayo. |
Condiciones de reacción | 0.3 mM |
Áreas de aplicación | (-)-p-Bromotetramisole Oxalate (0.3 mM) mejora la liberación de norepinefrina (NA) estimulada por ionomicina. |
| Experimentos con animales [2]: | |
Modelos animales | Ratas Sprague-Dawley |
Método de preparación | Se midió la excreción fraccionada de fosfato (FEPi) en ratas tiroparatiroidectomizadas antes y durante una infusión sistémica a 0.8 ml/min de 10 mM (-)-p-Bromotetramisole Oxalate. |
Forma de dosificación | 0.8 ml/min de 10 mM (-)-p-Bromotetramisole Oxalate; ivgtt |
Áreas de aplicación | La infusión sistémica de (-)-p-Bromotetramisole Oxalate aumenta la excreción fraccional de fosfato (FEPi) en ratas. |
| References: [1]. Kitamura T, Murayama T, et,al. Enhancement of Ca2+-induced noradrenaline release by vanadate in PC12 cells: possible involvement of tyrosine phosphorylation. Brain Res. 2000 Jan 31;854(1-2):165-71. doi: 10.1016/s0006-8993(99)02299-4. PMID: 10784118. | |
| Cas No. | 62284-79-1 | SDF | |
| Sinónimos | (-)-p-Bromotetramisole, L-para-Bromotetramisole | ||
| Canonical SMILES | BrC(C=C1)=CC=C1[C@H]2N=C3SCCN3C2.OC(C(O)=O)=O | ||
| Formula | C13H13BrN2O4S | M.Wt | 373.22 |
| Solubility | ≥ 18.65mg/mL in DMSO | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6794 mL | 13.3969 mL | 26.7938 mL |
| 5 mM | 535.9 μL | 2.6794 mL | 5.3588 mL |
| 10 mM | 267.9 μL | 1.3397 mL | 2.6794 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 1 reference(s) in Google Scholar.)